Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

Rheumatoid Arthritis (RA) Clinical Trial

— MAZERATI  

Official title:

Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02353780
• Other study ID #: STUDY19040127
• Status: Terminated
• Phase: Phase 4
• Start date: March 2015
• Est. completion date: November 30, 2018

Study information

• Verified date: September 2020
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An Agency for Healthcare Research and Quality executive summary indicated that better comparative effectiveness trial designs are needed to determine the relative merits of existing versus new and expensive biologic drug therapies for rheumatoid arthritis (RA). There are now 9 biologic therapies approved for treating RA. Four classes of biologics (TNF antagonists, B-cell inhibitors, T-cell co-stimulator blocker, and Interleukin-6 receptor blocker) are approved for use in RA patients with moderate or severe disease activity. Several critical questions have arisen, such as 1) what therapy should be prescribed after failure of methotrexate and/or other oral disease modifying antirheumatic drugs (DMARDs) to adequately control disease activity; 2) what is the level of efficacy of the various biologic therapies when compared in head-to-head trials; and 3) what are the mechanisms associated with failure of methotrexate and/or other oral DMARD therapy and responsiveness to biologic therapies. The MAZERATI study will provide the foundation for answering these questions and determining the mechanisms associated with these biologic therapies.

Description:

Single center, randomized, assessor-blinded, observational longitudinal assessment. Subjects will be randomized to treatment with an anti-TNF therapy, tocilizumab or abatacept and evaluated at baseline, and after 1, 3 and 6 months of therapy. All biologics will be administered subcutaneously (SQ). A blinded assessor will perform clinical disease activity assessments and blood samples will be obtained for mechanistic studies.

After randomization, patients must take at least one dose of the assigned medication and must maintain their baseline prednisone and oral disease modifying anti-rheumatic drug (DMARD) medications until they have received their first dose of assigned medication to be considered per protocol participants. During the first 3 months of therapy, patients and their physicians will be permitted to taper but not increase corticosteroids. Adjustments of study medication or oral DMARDs will not be permitted during the first 3 months of the study except as outlined in the protocol. Adjustments or additions of analgesics will be permitted throughout the study period.

Following randomization and treatment initiation, study participants will be seen in the clinic at 1 month (3-5 weeks), 3 months (10-14 weeks), and 6 months (22-30 weeks) after the initiation of therapy; at each time point, a blinded clinical disease activity assessment will occur and blood samples will be obtained for mechanistic studies. The occurrence and severity of unanticipated problems will be recorded continuously throughout the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: November 30, 2018
• Est. primary completion date: December 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Diagnosis of RA by a physician as defined by the 1987 and/or 2010 ACR criteria.

• 18 years of age or less than or equal to 64 at the time of diagnosis of RA.

• RA Disease Activity CDAI > 10

• If using oral corticosteroids, must have been on stable dose (= 10 mg/day) for at least 2 weeks prior to study drug initiation.

• PPD negative or if PPD positive documentation of therapy with INH for at least 1 month prior to study initiation and negative chest x-ray.

• Must have been treated within the past year with either methotrexate (MTX), leflunomide (LEF), hydrochloroquine (HCQ) and/or sulfasalazine (SSZ) for = 3 months.

• Prior or concurrent use of other oral DMARD therapy, including MTX, leflunomide, SSZ, and HCQ, is permitted. Patients taking oral DMARDs must be on stable doses of DMARDs for at least 4 weeks prior to study drug initiation. Subjects are not required to be taking an oral DMARD.

Exclusion Criteria:

• Use of cyclophosphamide, penicillamine, cyclosporine A, tacrolimus or gold therapy is not permitted in the 6 months prior to enrollment.

• Patients who are using or have used other biologic agents or tofacitinib concomitantly or prior to this study

• History of active and/or chronic infection such as hepatitis, pneumonia, pyelonephritis,herpetic infections or chronic skin infections and any active opportunistic infection, including but not limited to evidence of active cytomegalovirus, active Pneumocystis carinii, aspergillosis, histoplasmosis or atypical mycobacterium infection.

• Active TB or evidence of latent TB (positive PPD skin test or a history of old or latent TB on chest x-ray) without adequate therapy for TB.

• Pregnant or lactating women.

• Patients with current signs or symptoms of uncontrolled renal, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral disease.

• Diagnosis of liver disease or elevated hepatic enzymes, as defined by ALT, AST or both >1.5 x the upper limit of normal (ULN) or total bilirubin > ULN.

• Any of the following hematologic abnormalities, confirmed by repeat tests:

1. White blood count < 3,000/µL or > 14,000/µL

2. Lymphocyte count <500/µL

3. Platelet count < 100,000/µL

4. Hemoglobin < 8.0 g/dL

5. Neutrophil count < 2,000 cells/µL

• Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.

• Immunization with a live/attenuated vaccine within 2 months prior to baseline or 3 months of last study visit.

• History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies

• History of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer

• Patients with reproductive potential not willing to use an effective method of contraception

• History of alcohol, drug or chemical abuse with 1 year prior to screening

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis (RA)

Intervention

Drug:
• TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)
TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
• Abatacept
Abatacept; SQ; specifics to be determined by the treating rheumatologist.
• Tocilizumab
Tocilizumab; SQ; specifics determined by the treating rheumatologist.

Locations

Country	Name	City	State
United States	University of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Dr. Larry W. Moreland	Bristol-Myers Squibb, Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mechanistic Comparisons (Changes in Frequencies of Peripheral Blood Immune Cell Subsets Following Institution of a Subcutaneously Administered TNF Antagonist, Tocilizumab or Abatacept.)	There will be no primary efficacy endpoints for the study. The primary endpoint of the study will be changes in frequencies of peripheral blood immune cell subsets following institution of a subcutaneously administered TNF antagonist, tocilizumab or abatacept. Flow ctyometry was performed on peripheral blood T cells to determine frequency of Th17/TfH cells based on cell surface markers.	0 to 3 months
Secondary	Efficacy (CDAI)	Efficacy of therapy, as measured by number of participants with Clinical Disease Activity Index (CDAI) of less than 2.8 (remission). CDAI is a composite score of RA disease activity based on patient survey (up to 10 points), physician survey (up to 10 points), + number of swollen joints + number of tender joints. 0 = no disease, max score is 60, higher score = more severe disease. Number of patients achieving remission is reported.	0 to 3 months
Secondary	Efficacy (DAS)	Efficacy as measured by DAS remission with a DAS28-CRP < 2.4	3 month and 6 month
Secondary	ACR20, 50, and 70 Response	Efficacy as measured by ACR20, 50, and 70 response at 3 months and 6 months versus baseline	3 month and 6 month
Secondary	Efficacy (EULAR)	Efficacy as measured by European League against rheumatism (EULAR) response	3 month and 6 month
Secondary	Adherence	Adherence to drug regimen over course of clinical study	3 month and 6 month
Secondary	Steroid Use	Number of patients with steroid doses remaining below 10 mg/day	3 month and 6 month
Secondary	Corticosteroid Use	Average corticosteroid dose	3 month and 6 month
Secondary	DMARD Use	Number of patients without additional oral DMARDs or with a reduction in the number of oral DMARDs	3 month and 6 month
Secondary	Reason for Discontinuation of Treatment	Reason for discontinuation of treatment as provided by patient/provider (side effects, lack of efficacy, cost, patient compliance, etc.)	3 month and 6 month